Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 12/20 | 0.49 |
| ▸ | KDR | P35968 | 7/20 | 0.44 |
| ▸ | TEK | Q02763 | 4/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.42 |
| ▸ | JAK3 | P52333 | 4/20 | 0.42 |
| ▸ | PAICS | P22234 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5491403 | 0.92 | LCK (0.60) | LCKKDRTEKF10MAPK14 | |
| SCHEMBL5501412 | 0.91 | LCK (0.49) | LCKKDRTEKF10MAPK14 | |
| SCHEMBL5502207 | 0.89 | LCK (0.61) | LCKKDRTEKF10MAPK14 | |
| SCHEMBL5503625 | 0.87 | LCK (0.46) | LCKKDRTEKF10MAPK14 | |
| SCHEMBL5497767 | 0.87 | LCK (0.59) | LCKKDRTEKMAPK14JAK3 | |
| SCHEMBL5498568 | 0.87 | LCK (0.49) | LCKKDRTEKMAPK14JAK3 | |
| SCHEMBL5503720 | 0.86 | LCK (0.45) | LCKKDRTEKF10MAPK14 | |
| SCHEMBL5504114 | 0.86 | LCK (0.44) | LCKKDRTEKF10MAPK14 | |
| SCHEMBL5496681 | 0.86 | LCK (0.53) | LCKKDRTEKF10MAPK14 | |
| SCHEMBL5501869 | 0.85 | LCK (0.52) | LCKKDRTEKF10MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | LCK 106/4885KDR 1044/4885TEK 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.